Safety and Efficacy of Apremilast Through 104 Weeks in Patients swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 1, n. 3.1, p. s32, 2017. DOI: 10.25251/skin.1.supp.31. Disponível em: https://skin.dermsquared.com/skin/article/view/117. Acesso em: 14 apr. 2025.